A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved the treatment’s effectiveness in patients with metastatic gastrointestinal cancers, according to results of a clinical trial led by researchers at the National Institutes of Health (NIH). The findings, published April 1, 2025 in Nature Medicine, offer hopethat this therapy could be used to treat a variety of solid tumors, which has so far eluded researchers developing…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply